摘要
运用网状Meta分析对不同中成药联合抗生素治疗盆腔炎性疾病(PID)的疗效和安全性进行评价。检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Cochrane Library、EMbase、Web of Science数据库,搜索建库至2023年7月16日收录的中成药联合抗生素治疗PID的随机对照试验(RCT)。运用Cochrane风险偏倚工具对纳入文献进行质量评价,采用RevMan 5.4、Stata 16软件进行数据分析。最终纳入46篇RCTs,包含康妇消炎栓、妇科千金片/胶囊、康妇炎胶囊、妇炎消胶囊、花红片/胶囊、妇炎舒胶囊、妇乐片、金刚藤胶囊、妇炎康复胶囊。网状Meta分析显示,(1)临床有效率方面,排名第1的干预措施为康妇消炎栓+抗生素;(2)降低超敏C反应蛋白(hs-CRP)方面,排名第1的干预措施为花红片/胶囊+抗生素;(3)降低肿瘤坏死因子-α(TNF-α)方面,排名第1的干预措施为妇乐片+抗生素;(4)降低复发率方面,排名第1的干预措施为妇炎舒胶囊+抗生素;(5)安全性方面,不良反应最少的干预措施为康妇炎胶囊+抗生素。结果表明,中成药联合抗生素治疗PID能够提高综合疗效,降低患者hs-CRP和TNF-α,且复发率低,疗效安全可靠。临床治疗时,可优先选择康妇消炎栓或康妇炎胶囊联合抗生素。由于纳入文献样本量与文献质量等限制,结论有待更多大样本、高质量的研究加以验证。
To evaluate the efficacy and safety of different Chinese patent medicines in the treatment of pelvic inflammatory disease(PID)using network Meta-analysis.The databases of CNKI,Wanfang,VIP,SinoMed,PubMed,Cochrane Library,EMbase,and Web of Science were searched,and from the time of database construction to July 16,2023,the randomized controlled trial(RCT)of Chinese patent medicines combined with antibiotics in the treatment of PID included in these databases was collected.The quality of the included literature was evaluated using the Cochrane risk of bias tool,and data was analyzed using RevMan 5.4 and Stata 16 software.Forty-six RCTs were finally included,including Kangfu Xiaoyan Suppositories,Fuke Qianjin Tablets/Capsules,Kangfuyan Capsules,Fuyanxiao Capsules,Huahong Tablets/Capsules,Fuyanshu Capsules,Fuyue Tablets,Jingangteng Capsules,and Fuyan Kangfu Capsules.Network Meta-analysis showed that,①in terms of clinical effective rate,the optimal intervention was Kangfu Xiaoyan Suppositories combined with antibiotics.②In terms of lowering hypersensitive C-reactive protein(hs-CRP),the optimal intervention was Huahong Tablets/Capsules combined with antibiotics.③In terms of lowering tumor necrosis factor-α(TNF-α),the optimal intervention was Fuyue Tablets combined with antibiotics.④In terms of lowering recurrence rate,the optimal intervention was Fuyanshu Capsules combined with antibiotics.⑤In terms of safety,the intervention with the least adverse reactions was Kangfuyan Capsules combined with antibiotics.The results show that Chinese patent medicines combined with antibiotics in the treatment of PID can improve the comprehensive efficacy,reduce the patient′s hs-CRP and TNF-α,and have a low recurrence rate,as well as safe and reliable efficacy.In clinical treatment,Kangfu Xiaoyan Suppositories or Kangfuyan Capsules combined with antibiotics can be preferred.Due to the limitations of the sample size and the quality of the literature,more large-sample and high-quality studies are needed to validate the conclusions.
作者
马堃
黄天娇
曹仁爽
李芊
MA Kun;HUANG Tian-jiao;CAO Ren-shuang;LI Qian(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;the First School of Clinical Medicine,Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China;Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China;Postdoctoral Mobile Station,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2024年第8期2023-2036,共14页
China Journal of Chinese Materia Medica
基金
中国中医科学院第十一批自主选题项目(Z0546)。
关键词
中成药
盆腔炎性疾病
慢性盆腔疼痛综合征
网状Meta分析
Chinese patent medicine
pelvic inflammatory disease
chronic pelvic pain syndrome
network Meta-analysis
